PARG1 Antibody - BSA Free

Western Blot: PARG1 Antibody [NBP1-05989]

Western Blot: PARG1 Antibody [NBP1-05989] - Whole cell lysate from HeLa, 293T, and mouse NIH3T3 cells. PARG1 was also immunoprecipitated by rabbit anti-PARG1 antibody NBP1-05988.

Western Blot: PARG1 Antibody - BSA Free [NBP1-05989] -

(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, https://hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29-specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) p < 0.001; (**) p < 0.01; (*) p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PARG1 Antibody - BSA Free [NBP1-05989] -

(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, https://hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29-specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) p < 0.001; (**) p < 0.01; (*) p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.